Lario Therapeutics: Advancing Precision Medicines for Neurological Disorders
Lario Therapeutics, a promising biopharmaceutical company located in Edinburgh, Scotland, UK, has recently achieved a significant milestone in its quest to develop innovative treatments for epileptic and neurological disorders. The company announced that it has been awarded a substantial grant of $6 million from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This funding will play a crucial role in supporting the rigorous preclinical research of Lario’s CaV2.3 calcium channel inhibitors, which are being explored as a groundbreaking disease-modifying approach for treating Parkinson’s disease. The collaboration with the Oxford Parkinson’s Disease Centre is an essential aspect of this initiative, as they will provide vital scientific contributions that underpin the research efforts funded by the grant.
Under the leadership of CEO Henning Steinhagen and Chief Scientific Officer Tom Otis, Ph.
.D., who is also a Professor of Neuroscience at UCL, Lario Therapeutics is dedicated to the advancement of precision medicines specifically designed to address severe neurological conditions. The company's commitment to developing disease-modifying treatments encompasses not only Parkinson’s disease but also severe epileptic conditions, with the hope of making a profound impact on the lives of those affected by these challenging disorders. By focusing on genetically validated targets, Lario Therapeutics aims to establish a robust therapeutic pipeline that offers broad potential for effectively slowing the progression of debilitating illnesses that often manifest in early childhood or adulthood.
The strategic direction that Lario Therapeutics is pursuing emphasizes the importance of cutting-edge research and collaboration within the scientific community. The partnership with the Oxford Parkinson’s Disease Centre exemplifies Lario's dedication to integrating high-quality scientific input to enhance the overall efficacy of their research programs. As the world continues to grapple with the complexities of neurological disorders, initiatives like this one from Lario Therapeutics not only represent hope for affected individuals and their families but also reinforce the critical role of biopharmaceutical innovation in transforming patient care and advancing our understanding of these devastating conditions.
Click here for a full list of 6,528+ startup investors in the UK